MiNK Therapeutics
Update in progressINKT (NasdaqCM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
MiNK Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing allogeneic, off-the-shelf iNKT cell therapies to treat cancer and immune-mediated diseases. It is advancing agenT-797 in multiple trials, plus MiNK-215 and MiNK-413 programs, and collaborations with Autonomous Therapeutics, ImmunoScape, and C-Further. Formerly AgenTus Therapeutics, renamed in 2021. Founded 2017, based in New York, NY, and a subsidiary of Agenus Inc.
Company score
- Sentiment
- 0.34
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.16
- Governance
- 0.02
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.05
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.20
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqCM (NCM)
- LocationUnited States
- CEODr. Jennifer S. Buell Ph.D.
- Founded2017
- Employees15
- Websiteminktherapeutics.com
Identifiers
- ISINUS6036931029
- FIGIBBG012J84VS3
- CUSIP603693102
- CIK0001840229